Q4 2024 Earnings Call Transcript March 20, 2025 Abeona Therapeutics Inc. beats earnings expectations. Reported EPS is $-0.24, ...

Abeona Therapeutics Inc (NASDAQ:ABEO) is anticipating FDA approval for prademagene zamikeracel (pz-cel) for RDEB, with a PDUFA date set for April 29, 2025. The company has initiated label ...

Abeona Therapeutics Inc. (ABEO) reported its fourth-quarter earnings for 2024, significantly exceeding analysts’ expectations with an earnings per share (EPS) of $0.50, compared to the forecasted loss ...

On Thursday, Oppenheimer affirmed its positive stance on Abeona Therapeutics (NASDAQ:ABEO) shares, maintaining an Outperform rating and a $16.00 price target. The endorsement follows Abeona’s ...

Performance Date: March 22, 2026 The season will also include performances by Steven Isserlis, Sphinx Virtuosi, Emanuel Ax, Angela Hewitt, Abeo String Quartet, and Jeneba Kanneh-Mason. FRANCISCO ...

We will announce the names of the pz-cel qualified treatment centers as they become activated. Once a site is activated, they can begin to schedule patients for biopsy based on available ...

Abeona Therapeutics Inc. (ABEO) reported its fourth-quarter earnings for 2024, significantly exceeding analysts’ expectations with an earnings per share (EPS) of $0.50, compared to the ...

On Thursday, Oppenheimer affirmed its positive stance on Abeona Therapeutics (NASDAQ:ABEO) shares, maintaining an Outperform rating and a $16.00 price target. The endorsement follows Abeona’s ...

Abeona Therapeutics Inc. announced progress in its Biologics License Application (BLA) review for prademagene zamikeracel (pz-cel), a potential treatment for recessive dystrophic epidermolysis ...